{"id":"apatinib-and-etoposide-capsule","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hemorrhage"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Anorexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Apatinib's mechanism of action involves the inhibition of VEGFR2, which is involved in angiogenesis and tumor growth. Etoposide, on the other hand, works by forming a complex with the enzyme topoisomerase II, which is necessary for DNA replication and transcription. This complexation leads to the inhibition of DNA replication and transcription, ultimately resulting in cell death.","oneSentence":"Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), while Etoposide is a topoisomerase inhibitor that works by interfering with the enzyme topoisomerase II, thereby inhibiting DNA replication and transcription.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:43.388Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic gastric cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04501718","phase":"PHASE2","title":"Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children","status":"RECRUITING","sponsor":"Beijing Sanbo Brain Hospital","startDate":"2020-10-28","conditions":"Recurrent Medulloblastoma","enrollment":44},{"nctId":"NCT05142865","phase":"PHASE2","title":"Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2022-01-14","conditions":"Advanced or Metastatic EP-NEC","enrollment":30},{"nctId":"NCT04683198","phase":"PHASE2","title":"Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-04-01","conditions":"Small-cell Lung Cancer","enrollment":69},{"nctId":"NCT03389087","phase":"PHASE2","title":"Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2017-11-29","conditions":"Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT04383977","phase":"PHASE2","title":"Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-05","conditions":"Ovarian Cancer","enrollment":54},{"nctId":"NCT04000295","phase":"PHASE3","title":"Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-08-16","conditions":"Ovarian Cancer","enrollment":280}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Apatinib and Etoposide capsule","genericName":"Apatinib and Etoposide capsule","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), while Etoposide is a topoisomerase inhibitor that works by interfering with the enzyme topoisomerase II, thereby inhibiting DNA replication and transcription. Used for Metastatic gastric cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}